Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca Agrees with NicOx on CINODs Development
October 14, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 14, 2002
- NEW PRODUCTS
October 14, 2002
- DIAGNOSTIC NEWS IN BRIEF
October 14, 2002
- Alcon Japan Aims to Be Leader in Glaucoma Treatment: President Kodama
October 14, 2002
- OTC NEWS IN BRIEF
October 14, 2002
- Korosho to Take Action to Materialize Industry Vision
October 14, 2002
- Yamanouchi Aims at \570 Bil. Sales in FY2004: President Takenaka
October 14, 2002
- Korosho Plan for Healthcare Reform to Be Presented by End of November
October 14, 2002
- Healthcare Expenditures Down 1.6% in 2nd QTR VS 1st QTR
October 14, 2002
- REGULATORY NEWS IN BRIEF
October 14, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 14, 2002
- Physician-led Trials to Start on New Indication for Irinotecan
October 14, 2002
- Maurer's Healthcare Insight (34)
October 7, 2002
- BULLETIN
October 7, 2002
- JP Should Be in Greater Harmony with Pharmacopoeias from Other Countries: Seminar
October 7, 2002
- Pursuing Fusion & Application of Intellectual Property: Mr Nakamura of Nippon Kayaku
October 7, 2002
- Fujisawa to Enhance Profitability by Splitting Off Plants, Chemical Division
October 7, 2002
- REGULATORY NEWS IN BRIEF
October 7, 2002
- Nippon Chemiphar Ties Up with Ranbaxy of India
October 7, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…